StocksMedium•25 September 2026•
1 min read
FDA Approves Merck and Eisai Combination Therapy for Advanced Kidney Cancer
Key Facts
1The U.S. FDA approved WELIREG in combination with LENVIMA for certain adult patients with advanced renal cell carcinoma.
The U.S. Food and Drug Administration approved WELIREG in combination with LENVIMA for the treatment of adult patients with certain types of advanced renal cell carcinoma. Business Wire reported that the approval specifically applies to patients who have received prior systemic therapy, introducing a new combination option for advanced kidney cancer.
The regulatory decision was based on clinical data supporting the efficacy of the Merck and Eisai combination therapy. This approval strengthens the oncology portfolios of both companies as they continue to expand the indications for their existing therapeutic treatments in the advanced cancer market.